Safety and efficacy of liraglutide in type 2 diabetes: post marketing surveillance data from India

被引：0
|
作者：
Wangnoo, S. K. [1 ]
Mithal, A. [1 ]
Kumar, S. [2 ]
Modi, K. D. [3 ]
Shamanna, P. [4 ]
Shetty, R. [5 ]
机构：
[1] Indraprastha Apollo Hosp, Dept Endocrinol, New Delhi, India
[2] Sir Ganga Ram Hosp, Dept Endocrinol & Metab, New Delhi, India
[3] Dept Endocrinol, Hyderabad, Andhra Pradesh, India
[4] Bangalore Diabet Ctr, Bengalore, India
[5] Novo Nordisk India Pvt Ltd, Bangalore, Karnataka, India
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
732
引用
收藏
页码：S299 / S299
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Liraglutide in 195 Patients With Type 2 Diabetes in India: A Retrospective Analysis
    Kesavadev, Jothydev
    Shankar, Arun
    Gopalakrishnan, Gopikakrishnan
    Veeresh, Binushma
    Jothydev, Sunitha
    DIABETES, 2012, 61 : A605 - A606
  • [2] Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
    Neumiller, Joshua J.
    Sonnett, Travis E.
    Wood, Lindy D.
    Setter, Stephen M.
    Campbell, R. Keith
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2010, 3 : 215 - 226
  • [3] Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
    Masakazu Haneda
    Takashi Kadowaki
    Hiroshi Ito
    Kazuyo Sasaki
    Sonoe Hiraide
    Manabu Ishii
    Miyuki Matsukawa
    Makoto Ueno
    Diabetes Therapy, 2018, 9 : 1083 - 1097
  • [4] Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
    Haneda, Masakazu
    Kadowaki, Takashi
    Ito, Hiroshi
    Sasaki, Kazuyo
    Hiraide, Sonoe
    Ishii, Manabu
    Matsukawa, Miyuki
    Ueno, Makoto
    DIABETES THERAPY, 2018, 9 (03) : 1083 - 1097
  • [5] Efficacy and safety of acarbose in the treatment of Type 2 diabetes: data from a 2-year surveillance study
    Mertes, G
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1998, 40 (01) : 63 - 70
  • [6] Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan
    Goda, Maki
    Yamakura, Tomoko
    Sasaki, Kazuyo
    Tajima, Takumi
    Ueno, Makoto
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 319 - 327
  • [7] SAFETY AND EFFICACY OF LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY IN CLINICAL PRACTICE
    Dieguez, M.
    Riestra, M.
    Manjon, L.
    Veiguela, B.
    Tuson, C.
    Meana, A.
    Menendez, P.
    Blanco, M. J.
    Casal, F.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 : A130 - A130
  • [8] Post-marketing safety surveillance of the rotavirus vaccine in India
    Kang, Gagandeep
    Lakhkar, Anand
    Bhamare, Chetanraj
    Dharmadhikari, Abhijeet
    Narwadkar, Jyoti
    Kanujia, Arti
    Desai, Sajjad
    Gunale, Bhagwat
    Poonawalla, Cyrus S.
    Kulkarni, Prasad S.
    VACCINE: X, 2023, 15
  • [9] Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study
    Kaku, Kohei
    Chin, Rina
    Naito, Yusuke
    Iliev, Hristo
    Ikeda, Rie
    Ochiai, Kaori
    Yasui, Atsutaka
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (02) : 211 - 221
  • [10] Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
    Moon, Jun Sung
    Kim, Nam Hoon
    Na, Jin Oh
    Cho, Jae Hyoung
    Jeong, In-Kyung
    Lee, Soon Hee
    Mok, Ji-Oh
    Kim, Nan Hee
    Chung, Dong Jin
    Cho, Jinhong
    Lee, Dong Woo
    Lee, Sun Woo
    Won, Kyu Chang
    DIABETES & METABOLISM JOURNAL, 2023, 47 (01) : 82 - 91
12345